NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO
STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2022 – 30.06.2022. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
We are back in business in Denmark. Q2 2022 marked a milestone that we have been working hard to realize since 2019. We imported and began sales of our new THC Oil products to patients in Denmark. For Stenocare this means that we are back in business in Denmark. For doctors and patients, it means they now have a new option for treatment with medical cannabis.
|Operating profit before depreciation (EBITDA)||-3,933||-2,268||-7,354||-5,416|
|Net financial items||-343||-42||-358||-90|
|Investment in tangible fixed assets||366||552||1,541||2,964|
|Result per share (DKK)||-0.41||-0.19||-0.74||-0.44|
Result per share: The result for the period divided by the average number of shares. Total number of shares as of June 30, 2022, amounted to 11,676,126 (11,676,126). Average number of shares for the second quarter 2022 was 11,676,126 (11,676,126).
Solidity: Equity divided by total capital.
Highlights during the period
- STENOCARE has now completed the import of the new medical cannabis oil product into Denmark. The product is named THC Olie STENOCARE and is available in 30 mL bottles with a strength of 30 mg/mL THC and <0.1 mg/mL CBD. This marks the beginning of sales in Denmark.